Cargando…

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD

BACKGROUND AND AIMS: Glycoprotein acetylation [GlycA] is a novel nuclear magnetic resonance [NMR] biomarker, measured in serum or plasma, that summarizes the signals originating from glycan groups of certain acute-phase glycoproteins. This biomarker has been shown to be robustly associated with card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dierckx, Tim, Verstockt, Bram, Vermeire, Séverine, van Weyenbergh, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434738/ https://www.ncbi.nlm.nih.gov/pubmed/30312386 http://dx.doi.org/10.1093/ecco-jcc/jjy162

Ejemplares similares

Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity
por: Dierckx, Tim, et al.
Publicado: (2020)

GlycA: Evaluation of a New Biomarker of Acute Pancreatitis
por: Shah, Ishani, et al.
Publicado: (2023)

Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation
por: Assone, Tatiane, et al.
Publicado: (2022)

GlycA is not a useful biomarker of inflammation in sickle cell disease
por: Weisman, Julie K., et al.
Publicado: (2018)

GlycA, a marker of protein glycosylation, is related to albuminuria and estimated glomerular filtration rate: the ELSA-Brasil study
por: Titan, Silvia M., et al.
Publicado: (2017)

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
por: Connelly, Margery A., et al.
Publicado: (2017)

GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis: GlycA, hsCRP Differentially Associated MI, Stroke
por: Riggs, Kayla A., et al.
Publicado: (2022)

GlycA measured by NMR spectroscopy is associated with disease activity and cardiovascular disease risk in chronic inflammatory diseases()
por: Mehta, Nehal N., et al.
Publicado: (2020)

GlycA, a Biomarker of Low-Grade Inflammation, Is Increased in Male Night Shift Workers
por: Bizzarri, Daniele, et al.
Publicado: (2022)

Towards clinical application of GlycA and GlycB for early detection of inflammation associated with (pre)diabetes and cardiovascular disease: recent evidence and updates
por: Fung, Erik, et al.
Publicado: (2023)

Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events
por: Riggs, Kayla A., et al.
Publicado: (2019)

Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis
por: Ormseth, Michelle J., et al.
Publicado: (2015)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Association of the Composite Inflammatory Biomarker GlycA, with Exercise-Induced Changes in Body Habitus in Men and Women with Prediabetes
por: Bartlett, David B., et al.
Publicado: (2017)

The association of novel inflammatory marker GlycA and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis (MESA)
por: Jang, Sunyoung, et al.
Publicado: (2021)

Big data in IBD: big progress for clinical practice
por: Seyed Tabib, Nasim Sadat, et al.
Publicado: (2020)

GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2020)

Elevated serum alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality
por: Ritchie, Scott C., et al.
Publicado: (2019)

Increase in the Inflammatory Marker GlycA over 13 Years in Young Adults Is Associated with Poorer Cognitive Function in Midlife
por: Cohen-Manheim, Irit, et al.
Publicado: (2015)

GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function
por: Gruppen, Eke G., et al.
Publicado: (2015)

GlycA, a novel pro‐inflammatory glycoprotein biomarker is associated with mortality: results from the PREVEND study and meta‐analysis
por: Gruppen, E. G., et al.
Publicado: (2019)

A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls
por: Bartlett, David B., et al.
Publicado: (2016)

Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children
por: Connelly, Margery A., et al.
Publicado: (2016)

Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
por: Cleynen, Isabelle, et al.
Publicado: (2019)

The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
por: Puig-Jové, Carlos, et al.
Publicado: (2022)

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways
por: Prins, Marileen M., et al.
Publicado: (2021)

Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon
por: Verstockt, Bram, et al.
Publicado: (2020)

A Dietitian-Led Vegan Program May Improve GlycA, and Other Novel and Traditional Cardiometabolic Risk Factors in Patients With Dyslipidemia: A Pilot Study
por: Chiu, Tina H. T., et al.
Publicado: (2022)

GlycA, a novel marker for low grade inflammation, reflects gut microbiome diversity and is more accurate than high sensitive CRP in reflecting metabolomic profile
por: Mokkala, Kati, et al.
Publicado: (2020)

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
por: Alsoud, Dahham, et al.
Publicado: (2022)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Association Between Smoking and Serum GlycA and High‐Sensitivity C‐Reactive Protein Levels: The Multi‐Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil)
Publicado: (2017)

Association Between Smoking and Serum GlycA and High‐Sensitivity C‐Reactive Protein Levels: The Multi‐Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil)
por: Kianoush, Sina, et al.
Publicado: (2017)

New treatment options for inflammatory bowel diseases
por: Verstockt, Bram, et al.
Publicado: (2018)

JAK Inhibitors: Back to Small Molecules for the Treatment of IBD
por: Panés, Julian, et al.
Publicado: (2020)

Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
por: Sudhakar, Padhmanand, et al.
Publicado: (2020)

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions
por: Sudhakar, Padhmanand, et al.
Publicado: (2021)

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021)

Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
por: Jacobs, Inge, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hco24qnon25306sanlgbq9ha8v